The science of Tumor Treating Fields has the potential to extend beyond glioblastoma. Treatment with TTFields has shown a consistent antimitotic effect in our preclinical and clinical research over the last 16 years.
We believe we have gained a deep understanding of the underlying mechanism of action and the multiple pathways through which TTFields exert their effects within dividing cancer cells. Our research shows that TTFields can have an anti-mitotic effect in over 15 different solid tumor types in culture and in eight in vivo tumor models, including some of the most aggressive forms of cancer. We are committed to advancing the science of TTFields across a broad spectrum of solid tumors and bringing our treatment to cancer patients who can benefit from our therapy.
Novocure clinical pipeline
as of February 2017
Newly Diagnosed Glioblastoma
Non-small Cell Lung Cancer
we also have pre-clinical data for Tumor Treating Fields in these areas:
Novocure continues to test Tumor Treating Fields against a broad range of solid tumor types.
We sponsor clinical trials of Tumor Treating Fields in several cancer types. For more information on our ongoing clinical trials, visit novocuretrial.com and clinicaltrials.gov.
Cancer type: Brain metastases from non-small cell lung cancer Phase 3 pivotal
Protocol number: NCT02831959
About brain metastases: Metastatic cancer is cancer that has spread from the place where it first started to another place in the body. In metastasis, cancer cells break away from the primary cancer, travel through the blood or lymph system, and form new, metastatic tumors in other parts of the body. The exact incidence of brain metastases is unknown, but it has been estimated that 98,000 to 170,000 new cases are diagnosed in the United States each year. We believe approximately 40 percent of brain metastases originate from NSCLC. Brain metastases cause an estimated 20 percent of all cancer deaths in the United States annually.
About ovarian cancer: Ovarian cancer is the fifth most common cause of cancer death in women in the United States. The National Cancer Institute estimated that in 2015, there were approximately 21,000 new cases of ovarian cancer diagnosed and approximately 14,000 deaths in the United States. Ovarian cancer incidence increases with age, and the median age at time of diagnosis is 63 years old. The five-year survival rate is 44 percent, and the majority of patients present at advanced stage with 60 percent having metastatic disease.
Cancer type: Pancreatic adenocarcinoma Phase 2 pilot
Protocol number: NCT01971281
About pancreatic cancer: Most often diagnosed at a late stage, pancreatic cancer is one of the most lethal cancers. It is the fourth most frequent cause of death from cancer in the United States and is responsible for 7 percent of all U.S. cancer-related deaths. Unlike the decrease in mortality from other cancers over the past decade, pancreatic cancer death rates have been slowly increasing in the United States. Pancreatic cancer prognosis remains very poor, with a five-year survival of less than 6 percent. The National Cancer Institute estimated that, in 2015, there were approximately 49,000 new cases of pancreatic cancer diagnosed and approximately 40,000 deaths in the United States from pancreatic cancer.
About mesothelioma: Malignant mesothelioma is a rare thoracic solid tumor cancer that occurs in approximately 3,000 patients in the United States annually. Asbestos exposure has been strongly associated with the development of mesothelioma, which may occur many years later. Mesothelioma has a very poor prognosis, with a median overall survival of approximately 11 months in most reported studies.
We are planning a randomized phase 3 pivotal trial in NSCLC.
About NSCLC: Lung cancer is the leading cause of cancer-related death in the United States. NSCLC accounts for approximately 85 percent of all lung cancers. Approximately 185,000 new cases of NSCLC are diagnosed in the U.S. each year.
Additional investigator-sponsored trials are also ongoing. For the most up-to-date clinical trial information, including protocol details, please visit the U.S. National Institutes of Health’s website at clinicaltrials.gov.
This information is for medical, and scientific and educational purposes only. TTFields are experimental for the treatment of patients with brain metastases, ovarian carcinoma, pancreatic adenocarcinoma, mesothelioma and non-small cell lung cancer. TTFields has not been approved by the U.S. Food and Drug Administration for commercial use in these indications. Limited by federal law to investigational use only.
publicationsWe have more than 15 years of research and multiple peer-reviewed publications with pre-clinical data in 15 cancer types and clinical data in eight cancer types.
clinical trialsOur mechanism of action is broadly applicable across a variety of solid tumors.
novocuretrial.comThe science of Tumor Treating Fields extends beyond glioblastoma. We are conducting clinical trials in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.